Journey Medical Stock (NASDAQ:DERM)
Previous Close
$4.71
52W Range
$2.85 - $8.10
50D Avg
$5.55
200D Avg
$4.82
Market Cap
$97.14M
Avg Vol (3M)
$108.50K
Beta
0.92
Div Yield
-
DERM Company Profile
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use. It also sells doxycycline hyclate tablets, minocycline hydrocholoride capsules, and sulconazole nitrate cream and solution. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
DERM Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
| Product/Service | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|
| Amzeeq | $6.20M | $7.24M | - |
| Accutane | $20.17M | $18.37M | $10.05M |
| Zilxi | $1.96M | $2.27M | - |
| Ximino | $287.00K | $4.96M | $8.25M |
| Targadox | $3.20M | $7.97M | $22.38M |
| Qbrexza | $25.41M | $26.71M | - |
| Exelderm | $2.40M | $3.46M | $5.36M |
| Other Branded Products | - | - | $37.00K |
| Qbrexa | - | - | $17.06M |
Fiscal year ends in Dec 23 | Currency in USD